<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Dr Joe DiDuro on Medium]]></title>
        <description><![CDATA[Stories by Dr Joe DiDuro on Medium]]></description>
        <link>https://medium.com/@drjoe-69223?source=rss-f1bafdba7014------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/0*qxPW58_vEa4JzaFQ</url>
            <title>Stories by Dr Joe DiDuro on Medium</title>
            <link>https://medium.com/@drjoe-69223?source=rss-f1bafdba7014------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Tue, 17 Nov 2026 18:33:42 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@drjoe-69223/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Care for the Caregiver: A Novel, Home-based Therapy to Boost Caregiver Resiliency]]></title>
            <link>https://drjoe-69223.medium.com/care-for-the-caregiver-a-novel-home-based-therapy-to-boost-caregiver-resiliency-e0bfa66b8d91?source=rss-f1bafdba7014------2</link>
            <guid isPermaLink="false">https://medium.com/p/e0bfa66b8d91</guid>
            <category><![CDATA[depression-treatment]]></category>
            <category><![CDATA[elder-care]]></category>
            <category><![CDATA[sleep-disorders]]></category>
            <category><![CDATA[caregiving]]></category>
            <category><![CDATA[resilience]]></category>
            <dc:creator><![CDATA[Dr Joe DiDuro]]></dc:creator>
            <pubDate>Mon, 16 Jan 2023 21:14:03 GMT</pubDate>
            <atom:updated>2023-01-16T21:14:03.964Z</atom:updated>
            <content:encoded><![CDATA[<p>Dementia and cognitive disorders are among the major public health challenges of aging societies today. It has been estimated that approximately 36 million persons around the world are living with dementia, and this number will more than triple by the year 2050 [1 ]. When older adults can no longer live independently, informal caregivers (typically, family members) are called to assist. Over 16 million Americans, mainly nonprofessional family members, currently provide care for Americans living with dementia [2 ]. This would indicate that at least that number of family members; live at home adult children or spouses, are likely to be providing care or support for people with dementia (PwD). Spouses of PwD are generally elderly themselves and particularly vulnerable to the physical and emotional health effects of caregiving [ 2 ]. Faced with multiple, often complex and challenging tasks, beyond simple caring for the PwD: (doctors’ appointments, managing medications, perhaps therapy visits), assistance with basic activities of daily living (e.g., dressing, feeding, bathing, bathroom assistance). These non-trained caregivers must also navigate tasks alone like shopping, handling financial decisions and addressing legal matters. The ability to be an effective caregiver requires making appropriate judgments, solving problems, recalling necessary information, emotional regulation and effective communication [ 3 ]. Thus, a minimal level of cognitive ability would seem to be a prerequisite for adequately caring for another person. Spousal caregivers are usually of the same age as the PwD and therefore at risk of agerelated cognitive decline [4 ]. Suboptimal cognitive functioning in caregivers may have profound implications for the vast responsibilities placed upon them. We recognize that due to the slow progressive nature of neurodegenerative diseases, spousal or family caregivers may be required to provide years of extensive care for their partner or parent and must be able to adapt to a continuously changing and demanding situation. The ability to provide care at home for a demented partner may be compromised by caregiver burden related to; cognitive decline, depression and sleep disorders. These factors impact overall caregiver resiliency, defined as the ability to adapt to chronic stressors. Such stressors are associated with both the onset of new illnesses and with accelerated disease progression among those who are already ill. The relationship between caregiving and poor physical health is especially strong among older caregivers, dementia caregivers, and spouse caregiver [2 ]. The caregivers of PwD (CPwD) show increased risk of health problems such as; decreased immune system functioning, cardiovascular problems and increased physical symptoms over time compared with demographically matched controls [ 2 ]. Cognitive decline is documented in CPwD as caregivers performed significantly worse on several cognitive domains compared with control subjects. Low performance on a verbal memory task was related to a decrease in caregiver subjective competence and an increase in patient hyperactivity [ 4 ]. Notably, the authors recommended that screening for cognitive impairment of spousal caregivers may be helpful, because suboptimal cognitive functioning may affect the ability to provide adequate care. Vitalano’s group evaluated the relationship between caregiver status and decline on the digit symbol test (DST; a measure of processing speed, attention, cognitive — motor translation, and visual scanning) and found CPwD had lower DST scores and higher Hamilton depression scores. Depressed mood is a antecedent or a comorbid consequence to cognitive decline in CPwD who declined 4.5 times faster than noncaregivers. This is important because the DST predicts problem solving and everyday functions necessary for stay-at-home living and impacts potential well-being of their relative PwD [6 ]. These spousal caregivers often provide years of extensive care for their partner and must be able to adapt to a continuously changing and demanding situation. The quality of life of both patient and caregiver and the ability to provide care at home are greatly dependent upon the ability of the caregiver to adequately adapt and respond to the problems and needs of the patient. This ability to effectively care for a demented partner may be compromised by cognitive decline. Caregiver wives of PwD seem to be more at risk than caregiver husbands. They report higher levels of depression and nonspecific physical symptoms such as headaches, dizziness, and sleep problems than do husbands caring for demented spouses [ 7 ]. Wife caregivers of CPwD had significantly higher emotional strain scores than husband caregivers [ 8 ]. And this in turn may be reflected in results revealed that CPwD had significantly greater cognitive decline compared to nondementia caregivers [9 ]. A CPwD whose spouse experienced incident dementia onset had a six-fold increase in the hazard for incident dementia compared to subjects whose spouses were dementia free [ 10]. Even in people with mild cognitive impairment (MCI), viewed as a predementia clinical stage bridging between normal aging and dementia, pose considerable challenges not only for the individuals with MCI, but also for their family members who assume the role of caregiver almost inadvertently. Sadness, anxiety, fatigue, and sleep disorders were reported as the main stressors by CPwD and its impact was rated as ‘severe’ in 50% of case [ 11]. It appears that dementia, whatever underlying pathology or cognitive profile, generates significant caregiver burden. They astutely observed that the sole experience of seeing a loved one go through phases of significant loss is sufficient to increase the amount of distress, irrespective of diagnosis. In fact, perceived sleep quality was a mediator in cognitive differences between CPwD and noncaregivers that involve timed and attention tasks[ 5 ]. Whatever the mechanism, clinicians need to be aware of possible cognitive changes among CPwD since it may impact their ability to provide optimal care. From a different angle, Abulafia’s work on late-onset Alzheimer’s disease (LOAD) identified early brain alterations in regions subserving executive functions in asymptomatic, middle-aged (53 yoa) offspring of patients with LOAD (O-LOAD) [ 12]. These asymptomatic family members may also be caregivers who may present with premature episodic memory deficits and executive dysfunction. In another of her studies, they tested 31 children of patients with LOAD (O-LOAD) and 19 healthy individuals without family history of Alzheimer’s disease (control subjects, CS) with basic tests of cognitive function, as well as actigraphy measures of sleep–wake rhythm, cardiac autonomic function, and bodily temperature. Unexpectedly, O-LOAD displayed subtle but significant deficits in verbal episodic memory (Rey Auditory Verbal Learning Test delayed recall) and language (Weschler’s vocabulary) compared to CS, even though all participants had results within the clinically normal range. O-LOAD individuals showed a phase-delayed rhythm of body and cognitive performance related to poorer cognition [ 13]. What this is indicating is that O-LOAD already show deficits in sleep cycles and cognition, before accepting the role of CPwD. They also studied middle-aged cognitively normal individuals with one parent affected with LOAD, recovery ability on a cognitive “stress test” was impaired compared with persons without a family history of LOAD. This was also documented in MRI correlations between grey matter integrity and in vivo amyloid deposition and the ability to recover from the cognitive “stress test”[14]. Researchers also observed isocortical thinning in AD-relevant areas including posterior cingulate, precuneus, and areas of the prefrontal and temporoparietal cortex in O-LOAD [ 15]. Furthermore, results showed lower cognitive performance in verbal episodic memory and semantic memory in a LOAD parent, especially if the mother was the PwD. Depressive symptoms can affect cognitive performance differently in individuals with a LOAD parents compared to a control group [ 16]. In summary, examining the factors of cognition, sleep and depression that are in play in spousal CPwD and also in asymptomatic children (O-LOAD) that may become CPwD would indicate an additional unforeseen risk agent and an exponential explosion in MCI and demented individuals. Could there be a safe and effective way to curtail the risk factors for caregiver burn out and possibly improve the physiology of the caregiver dyad? Transcranial photobiomodulation (tPBMT) is a new therapeutic instrument that has been shown in the literature to impact the parameters we are investigating here. Inside the clinical trials and case reports, one can see that: as the PwD improves, caregiver stress and burden is reduced [17,18]. It is logical that improved cognitive test scores were supported by improved QoL feedback from patients and caregivers. Improvements were noted in the areas of functional abilities (i.e., decreased incontinence, increased mobility), sleep, fewer angry outbursts, less anxiety, and wandering. Caregivers expressed a better QoL for themselves during the active treatment period when behavior was improved in the patients [ 19]. This is with just the PwD applying the tPBMT devices. We are suggesting that CPwD utilize these same devices for maximal recovery and increased resiliency. When we address the concept improvement in cognitive function from tPBMT, the literature is growing both in PwD [17–23], MCI [22,24–26] and healthy individuals [27–32]. Examining the effects of tPBMT on emotional well-being, again the research shows positive changes in depressive mood and major depressive disorder [33–44]. CPwD must first become aware of their own emotional vulnerability and then become familiar with these new methods of addressing psychological health. One of the main factors influencing PwD and caregiver burden is the aspect of poor sleep. While no systemic review of literature exists on the topic, sufficient reports are emerging that indicate tPBMT improves sleep performance [17,45–56]. These results along with no side effects being reported and the therapy being easily accessible as home based care [17,18,49,50,56], appear to create the perfect environment to produce significant improvements in cognition, increase in functional daily abilities, better sleep performance, decreased depression and improved QoL of everyone under that roof. The introduction of a novel, home-based therapy to boost caregiver resiliency has the potential to reduce or prevent the deleterious effect of caregiving for our loved ones with neurodegenerative disorders.</p><p>(1) Wortmann, M. Dementia: A Global Health Priority — Highlights from an ADI and World Health Organization Report. Alzheimers Res. Ther. 2012, 4 (5), 40. <a href="https://doi.org/10.1186/alzrt143.">https://doi.org/10.1186/alzrt143.</a></p><p>(2) Mittelman, M. S.; Roth, D. L.; Clay, O. J.; Haley, W. E. Preserving Health of Alzheimer Caregivers: Impact of a Spouse Caregiver Intervention. Am. J. Geriatr. Psychiatry Off. J. Am. Assoc. Geriatr. Psychiatry 2007, 15 (9), 780–789. <a href="https://doi.org/10.1097/JGP.0b013e31805d858a.">https://doi.org/10.1097/JGP.0b013e31805d858a.</a></p><p>(3) Miller, L. S.; Lewis, M. S.; Williamson, G. M.; Lance, C. E.; Dooley, W. K.; Schulz, R.; Weiner, M. F. Caregiver Cognitive Status and Potentially Harmful Caregiver Behavior. Aging Ment. Health 2006, 10 (2), 125–133. <a href="https://doi.org/10.1080/13607860500310500.">https://doi.org/10.1080/13607860500310500.</a></p><p>(4) de Vugt, M. E.; Jolles, J.; van Osch, L.; Stevens, F.; Aalten, P.; Lousberg, R.; Verhey, F. R. J. Cognitive Functioning in Spousal Caregivers of Dementia Patients: Findings from the Prospective MAASBED Study. Age Ageing 2006, 35 (2), 160–166. <a href="https://doi.org/10.1093/ageing/afj044.">https://doi.org/10.1093/ageing/afj044.</a></p><p>(5) Oken, B. S.; Fonareva, I.; Wahbeh, H. Stress-Related Cognitive Dysfunction in Dementia Caregivers. J. Geriatr. Psychiatry Neurol. 2011, 24 (4), 191–198. <a href="https://doi.org/10.1177/0891988711422524.">https://doi.org/10.1177/0891988711422524.</a></p><p>(6) Vitaliano, P. P.; Zhang, J.; Young, H. M.; Caswell, L. W.; Scanlan, J. M.; Echeverria, D. Depressed Mood Mediates Decline in Cognitive Processing Speed in Caregivers. The Gerontologist 2009, 49 (1), 12– 22. <a href="https://doi.org/10.1093/geront/gnp004.">https://doi.org/10.1093/geront/gnp004.</a></p><p>(7) Rose-Rego, S. K.; Strauss, M. E.; Smyth, K. A. Differences in the Perceived Well-Being of Wives and Husbands Caring for Persons with Alzheimer’s Disease. The Gerontologist 1998, 38 (2), 224–230. <a href="https://doi.org/10.1093/geront/38.2.224.">https://doi.org/10.1093/geront/38.2.224.</a></p><p>(8) Hooker, K.; Manoogian-O’Dell, M.; Monahan, D. J.; Frazier, L. D.; Shifren, K. Does Type of Disease Matter? Gender Differences Among Alzheimer’s and Parkinson’s Disease Spouse Caregivers. The Gerontologist 2000, 40 (5), 568–573. <a href="https://doi.org/10.1093/geront/40.5.568.">https://doi.org/10.1093/geront/40.5.568.</a></p><p>(9) Dassel, K. B.; Carr, D. C.; Vitaliano, P. Does Caring for a Spouse With Dementia Accelerate Cognitive Decline? Findings From the Health and Retirement Study. The Gerontologist 2017, 57 (2), 319– 328. <a href="https://doi.org/10.1093/geront/gnv148.">https://doi.org/10.1093/geront/gnv148.</a></p><p>(10) Norton, M. C.; Smith, K. R.; Østbye, T.; Tschanz, J. T.; Corcoran, C.; Schwartz, S.; Piercy, K. W.; Rabins, P. V.; Steffens, D. C.; Skoog, I.; Breitner, J. C. S.; Welsh-Bohmer, K. A. Increased Risk of Dementia When Spouse Has Dementia? The Cache County Study. J. Am. Geriatr. Soc. 2010, 58 (5), 895–900. <a href="https://doi.org/10.1111/j.1532-5415.2010.02806.x.">https://doi.org/10.1111/j.1532-5415.2010.02806.x.</a></p><p>(11) Pilon, M.-H.; Poulin, S.; Fortin, M.-P.; Houde, M.; Verret, L.; Bouchard, R. W.; Laforce, R. Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer’s Disease and Vascular Dementia: A Retrospective Study. Neurol. E-Cronicon 2016, 2 (6), 278–286.</p><p>(12) Abulafia, C.; Fiorentini, L.; Loewenstein, D. A.; Curiel-Cid, R.; Sevlever, G.; Nemeroff, C. B.; Villarreal, M. F.; Vigo, D. E.; Guinjoan, S. M. Executive Functioning in Cognitively Normal Middle-Aged Offspring of Late-Onset Alzheimer’s Disease Patients. J. Psychiatr. Res. 2019, 112, 23–29. <a href="https://doi.org/10.1016/j.jpsychires.2019.02.016.">https://doi.org/10.1016/j.jpsychires.2019.02.016.</a></p><p>(13) Abulafia, C.; Duarte-Abritta, B.; Villarreal, M. F.; Ladrón-de-Guevara, M. S.; García, C.; Sequeyra, G.; Sevlever, G.; Fiorentini, L.; Bär, K.-J.; Gustafson, D. R.; Vigo, D. E.; Guinjoan, S. M. Relationship between Cognitive and Sleep–Wake Variables in Asymptomatic Offspring of Patients with Late-Onset Alzheimer’s Disease. Front. Aging Neurosci. 2017, 9. <a href="https://doi.org/10.3389/fnagi.2017.00093.">https://doi.org/10.3389/fnagi.2017.00093.</a></p><p>(14) Abulafia, C.; Loewenstein, D.; Curiel-Cid, R.; Duarte-Abritta, B.; Sánchez, S. M.; Vigo, D. E.; Castro, M. N.; Drucaroff, L. J.; Vázquez, S.; Sevlever, G.; Nemeroff, C. B.; Guinjoan, S. M.; Villarreal, M. F. Brain Structural and Amyloid Correlates of Recovery From Semantic Interference in Cognitively Normal Individuals With or Without Family History of Late-Onset Alzheimer’s Disease. J. Neuropsychiatry Clin. Neurosci. 2019, 31 (1), 25–36. <a href="https://doi.org/10.1176/appi.neuropsych.17120355.">https://doi.org/10.1176/appi.neuropsych.17120355.</a></p><p>(15) Duarte-Abritta, B.; Villarreal, M. F.; Abulafia, C.; Loewenstein, D.; Curiel Cid, R. E.; Castro, M. N.; Surace, E.; Sánchez, S.-M.; Vigo, D. E.; Vázquez, S.; Nemeroff, C. B.; Sevlever, G.; Guinjoan, S. M. Cortical Thickness, Brain Metabolic Activity, and in Vivo Amyloid Deposition in Asymptomatic, Middle-Aged Offspring of Patients with Late-Onset Alzheimer’s Disease. J. Psychiatr. Res. 2018, 107, 11–18. <a href="https://doi.org/10.1016/j.jpsychires.2018.10.008.">https://doi.org/10.1016/j.jpsychires.2018.10.008.</a></p><p>(16) Wilson, K. E.; Abulafia, C.; Loewenstein, D. A.; Vigo, D. E.; Sevlever, G.; Nemeroff, C. B.; Villarreal, M. F.; Guinjoan, S. M. Individual Cognitive and Depressive Traits Associated with Maternal versus Paternal Family History of Late-Onset Alzheimer’s Disease: Proactive Semantic Interference versus Standard Neuropsychological Assessments. Pers. Med. Psychiatry 2018, 11–12, 1–6. <a href="https://doi.org/10.1016/j.pmip.2018.09.002.">https://doi.org/10.1016/j.pmip.2018.09.002.</a></p><p>(17) Nizamutdinov, D.; Qi, X.; Berman, M. H.; Dougal, G.; Wu, E.; Yi, S. S.; Stevens, A. B.; Huang, J. H. Transcranial Near Infrared Light Stimulations Improve Cognition in Patients with Dementia. Aging Dis. 2021, 12 (5), 10.</p><p>(18) Salehpour, F.; Hamblin, M. R.; DiDuro, J. O. Rapid Reversal of Cognitive Decline, Olfactory Dysfunction, and Quality of Life Using Multi-Modality Photobiomodulation Therapy: Case Report. Photobiomodulation Photomed. Laser Surg. 2019, 37 (3), 159–167. <a href="https://doi.org/10.1089/photob.2018.4569.">https://doi.org/10.1089/photob.2018.4569.</a></p><p>(19) Saltmarche, A. E.; Naeser, M. A.; Ho, K. F.; Hamblin, M. R.; Lim, L. Significant Improvement in Cognition in Mild to Moderately Severe Dementia Cases Treated with Transcranial Plus Intranasal Photobiomodulation: Case Series Report. Photomed. Laser Surg. 2017, 35 (8), 432–441. <a href="https://doi.org/10.1089/pho.2016.4227.">https://doi.org/10.1089/pho.2016.4227.</a></p><p>(20) Hamilton, C.; Hamilton, D.; Nicklason, F.; El Massri, N.; Mitrofanis, J. Exploring the Use of Transcranial Photobiomodulation in Parkinson’s Disease Patients. Neural Regen. Res. 2018, 13 (10), 1738. <a href="https://doi.org/10.4103/1673-5374.238613.">https://doi.org/10.4103/1673-5374.238613.</a></p><p>(21) Berman, M. H.; Nichols, T. W. Treatment of Neurodegeneration: Integrating Photobiomodulation and Neurofeedback in Alzheimer’s Dementia and Parkinson’s: A Review. Photobiomodulation Photomed. Laser Surg. 2019, 37 (10), 623–634. <a href="https://doi.org/10.1089/photob.2019.4685.">https://doi.org/10.1089/photob.2019.4685.</a></p><p>(22) Baik, J. S.; Lee, T. Y.; Kim, N. G.; Pak, K.; Ko, S.-H.; Min, J. H.; Shin, Y.-I. Effects of Photobiomodulation on Changes in Cognitive Function and Regional Cerebral Blood Flow in Patients with Mild Cognitive Impairment: A Pilot Uncontrolled Trial. J. Alzheimers Dis. 2021, Preprint (Preprint), 1–7. <a href="https://doi.org/10.3233/JAD-210386.">https://doi.org/10.3233/JAD-210386.</a></p><p>(23) Chang, J.; Ren, Y.; Wang, R.; Li, C.; Wang, Y.; Ping Chu, X. Transcranial Low-Level Laser Therapy for Depression and Alzheimer’s Disease. Neuropsychiatry 2018, 08 (02). <a href="https://doi.org/10.4172/Neuropsychiatry.1000369.">https://doi.org/10.4172/Neuropsychiatry.1000369.</a></p><p>(24) Chan, A. S.; Lee, T.; Hamblin, M. R.; Cheung, M. Photobiomodulation Enhances Memory Processing in Older Adults with Mild Cognitive Impairment: A Functional Near-Infrared Spectroscopy Study. J. Alzheimers Dis. 2021, Preprint (Preprint), 1–10. <a href="https://doi.org/10.3233/JAD-201600.">https://doi.org/10.3233/JAD-201600.</a></p><p>(25) Chan, A. S.; Lee, T. L.; Yeung, M. K.; Hamblin, M. R. Photobiomodulation Improves the Frontal Cognitive Function of Older Adults. Int. J. Geriatr. Psychiatry 2019, 34 (2), 369–377. <a href="https://doi.org/10.1002/gps.5039.">https://doi.org/10.1002/gps.5039.</a></p><p>(26) Agnes S, C.; TszLok, L.; Sophia, S.; Michael R, H. Photobiomodulation Improves Memory in Mild Cognitive Impairment: Three Case Reports. Alzheimers Dis. Dement. 2021, 5 (1). <a href="https://doi.org/10.36959/734/383.">https://doi.org/10.36959/734/383.</a></p><p>(27) Pruitt, T.; Wang, X.; Wu, A.; Kallioniemi, E.; Husain, M. M.; Liu, H. Transcranial Photobiomodulation (TPBM) With 1,064-Nm Laser to Improve Cerebral Metabolism of the Human Brain In Vivo. Lasers Surg. Med. 2020, 52 (9), 807–813. <a href="https://doi.org/10.1002/lsm.23232.">https://doi.org/10.1002/lsm.23232.</a></p><p>(28) Chan, A. S.; Yeung, M. K.; Lee, T. L. Can Photobiomodulation Enhance Brain Function in Older Adults? In Photobiomodulation in the Brain; Elsevier, 2019; pp 427–446. <a href="https://doi.org/10.1016/B978-">https://doi.org/10.1016/B978-</a> 0–12–815305–5.00031–2.</p><p>(29) Holmes, E.; Barrett, D. W.; Saucedo, C. L.; O’Connor, P.; Liu, H.; Gonzalez-Lima, F. Cognitive Enhancement by Transcranial Photobiomodulation Is Associated With Cerebrovascular Oxygenation of the Prefrontal Cortex. Front. Neurosci. 2019, 13, 1129. <a href="https://doi.org/10.3389/fnins.2019.01129.">https://doi.org/10.3389/fnins.2019.01129.</a></p><p>(30) Chan, A. S.; Lee, T.; Hamblin, M. R.; Cheung, M. OPEN Photoneuromodulation Makes a Difficult Cognitive Task Less Arduous. Sci. Rep. 10.</p><p>(31) Saucedo, C. L.; Courtois, E. C.; Wade, Z. S.; Kelley, M. N.; Kheradbin, N.; Barrett, D. W.; GonzalezLima, F. Transcranial Laser Stimulation: Mitochondrial and Cerebrovascular Effects in Younger and Older Healthy Adults. Brain Stimulat. 2021, 14 (2), 440–449. <a href="https://doi.org/10.1016/j.brs.2021.02.011.">https://doi.org/10.1016/j.brs.2021.02.011.</a></p><p>(32) Wang, X.; Dmochowski, J. P.; Zeng, L.; Kallioniemi, E.; Husain, M.; Gonzalez-Lima, F.; Liu, H. Transcranial Photobiomodulation with Infrared Laser Increases Power of Brain Oscillations; preprint; Bioengineering, 2019. <a href="https://doi.org/10.1101/535757.">https://doi.org/10.1101/535757.</a></p><p>(33) Gabel, C. A Case Control Series for the Effect of Photobiomodulation in Patients with Low Back Pain and Concurrent Depression: PBM for Low Back Pain and Depression. LASER Ther. 2018, 27, 167– 173. <a href="https://doi.org/10.5978/islsm.27_18-OR-18.">https://doi.org/10.5978/islsm.27_18-OR-18.</a></p><p>(34) Cassano, P.; Dording, C.; Thomas, G.; Foster, S.; Yeung, A.; Uchida, M.; Hamblin, M. R.; Bui, E.; Fava, M.; Mischoulon, D.; Iosifescu, D. V. Effects of Transcranial Photobiomodulation with Near-Infrared Light on Sexual Dysfunction: PHOTOBIOMODULATION FOR SEXUAL DYSFUNCTION. Lasers Surg. Med. 2019, 51 (2), 127–135. <a href="https://doi.org/10.1002/lsm.23011.">https://doi.org/10.1002/lsm.23011.</a></p><p>(35) Caldieraro, M. A.; Sani, G.; Bui, E.; Cassano, P. Long-Term Near-Infrared Photobiomodulation for Anxious Depression Complicated by Takotsubo Cardiomyopathy. J. Clin. Psychopharmacol. 2018, 38 (3), 268–270. <a href="https://doi.org/10.1097/JCP.0000000000000883.">https://doi.org/10.1097/JCP.0000000000000883.</a></p><p>(36) Cassano, P.; Cusin, C.; Mischoulon, D.; Hamblin, M. R.; De Taboada, L.; Pisoni, A.; Chang, T.; Yeung, A.; Ionescu, D. F.; Petrie, S. R.; Nierenberg, A. A.; Fava, M.; Iosifescu, D. V. Near-Infrared Transcranial Radiation for Major Depressive Disorder: Proof of Concept Study. Psychiatry J. 2015, 2015, 1–8. <a href="https://doi.org/10.1155/2015/352979.">https://doi.org/10.1155/2015/352979.</a></p><p>(37) Gutiérrez-Menéndez, A.; Marcos-Nistal, M.; Méndez, M.; Arias, J. L. Photobiomodulation as a Promising New Tool in the Management of Psychological Disorders: A Systematic Review. Neurosci. Biobehav. Rev. 2020, 119, 242–254. <a href="https://doi.org/10.1016/j.neubiorev.2020.10.002.">https://doi.org/10.1016/j.neubiorev.2020.10.002.</a></p><p>(38) Marks, R. Photobiomodulation, Depression, Anxiety, and Cognition. J. Aging Res. Healthc. 2021, 4 (1), 30–42. <a href="https://doi.org/10.14302/issn.2474-7785.jarh-21-3935.">https://doi.org/10.14302/issn.2474-7785.jarh-21-3935.</a></p><p>(39) Cassano, P.; Tran, A. P.; Katnani, H.; Bleier, B. S.; Hamblin, M. R.; Yuan, Y.; Fang, Q. Selective Photobiomodulation for Emotion Regulation: Model-Based Dosimetry Study. Neurophotonics 2019, 6 (01), 1. <a href="https://doi.org/10.1117/1.NPh.6.1.015004.">https://doi.org/10.1117/1.NPh.6.1.015004.</a></p><p>(40) Kerppers, F. K.; Dos Santos, K. M. M. G.; Cordeiro, M. E. R.; da Silva Pereira, M. C.; Barbosa, D.; Pezzini, A. A.; Cunha, L. F.; Fonseca, M.; Bragnholo, K.; Salgado, A. S. I.; Kerppers, I. I. Study of Transcranial Photobiomodulation at 945-Nm Wavelength: Anxiety and Depression. Lasers Med. Sci. 2020, 35 (9), 1945–1954. <a href="https://doi.org/10.1007/s10103-020-02983-7.">https://doi.org/10.1007/s10103-020-02983-7.</a></p><p>(41) Caldieraro, M. A.; Salehpour, F.; Cassano, P. Transcranial and Systemic Photobiomodulation for the Enhancement of Mitochondrial Metabolism in Depression. In Clinical Bioenergetics; Elsevier, 2021; pp 635–651. <a href="https://doi.org/10.1016/B978-0-12-819621-2.00028-0.">https://doi.org/10.1016/B978-0-12-819621-2.00028-0.</a></p><p>(42) Barrett, D. W.; Gonzalez-Lima, F. Transcranial Infrared Laser Stimulation Produces Beneficial Cognitive and Emotional Effects in Humans. Neuroscience 2013, 230, 13–23. <a href="https://doi.org/10.1016/j.neuroscience.2012.11.016.">https://doi.org/10.1016/j.neuroscience.2012.11.016.</a></p><p>(43) Caldieraro, M. A.; Cassano, P. Transcranial Photobiomodulation for Major Depressive and Anxiety Disorders and for Posttraumatic Stress Disorder. In Photobiomodulation in the Brain; Elsevier, 2019; pp 479–487. <a href="https://doi.org/10.1016/B978-0-12-815305-5.00035-X.">https://doi.org/10.1016/B978-0-12-815305-5.00035-X.</a></p><p>(44) Chang, J.; Ren, Y.; Wang, R.; Li, C.; Wang, Y.; Ping Chu, X. Transcranial Low-Level Laser Therapy for Depression and Alzheimer’s Disease. Neuropsychiatry 2018, 08 (02). <a href="https://doi.org/10.4172/Neuropsychiatry.1000369.">https://doi.org/10.4172/Neuropsychiatry.1000369.</a> (45) Jurvelin, H. Transcranial Bright Light : The Effect on Human Psychophysiology. 92.</p><p>(46) Naeser, M. A.; Martin, P. I.; Ho, M. D.; Krengel, M. H.; Bogdanova, Y.; Knight, J. A.; Yee, M. K.; Zafonte, R.; Frazier, J.; Hamblin, M. R.; Koo, B.-B. Transcranial, Red/Near-Infrared Light-Emitting Diode Therapy to Improve Cognition in Chronic Traumatic Brain Injury. 18.</p><p>(47) Bogdanova, Y.; Yee, M. K.; Gilbert, K. S.; Kark, S. M.; Ho, V. T.; Naeser, M. A. Non-Invasive Neuromodulation Interventions for Sleep Disturbance in Traumatic Brain. 5.</p><p>(48) Bogdanova, Y.; Martin, P. I.; Ho, M. D.; Krengel, M. H.; Ho, V. T.; Yee, M. K.; Knight, J. A.; Hamblin, M.; Naeser, M. LED Therapy Improves Sleep and Cognition In Chronic Moderate TBI: Pilot Case Studies. Arch. Phys. Med. Rehabil. 2014, 95 (10), e77. <a href="https://doi.org/10.1016/j.apmr.2014.07.247.">https://doi.org/10.1016/j.apmr.2014.07.247.</a></p><p>(49) Martin, P. I.; Chao, L.; Krengel, M. H.; Ho, M. D.; Yee, M.; Lew, R.; Knight, J.; Hamblin, M. R.; Naeser, M. A. Transcranial Photobiomodulation to Improve Cognition in Gulf War Illness. Front. Neurol. 2021, 11, 574386. <a href="https://doi.org/10.3389/fneur.2020.574386.">https://doi.org/10.3389/fneur.2020.574386.</a></p><p>(50) Bogdanova, Y. Virtual Neurorehabilitation: LED Home-Based Program for Veterans with TBI and PTSD. 3.</p><p>(51) Santana-Blank, L.; Rodríguez-Santana, E. Photobiomodulation in Light of Our Biological Clock’s Inner Workings. Photomed. Laser Surg. 2018, 36 (3), 119–121. <a href="https://doi.org/10.1089/pho.2018.4445.">https://doi.org/10.1089/pho.2018.4445.</a></p><p>(52) Hamper, M.; Cassano, P.; Lombard, J. Treatment of Kleine-Levin Syndrome With Intranasal Photobiomodulation and Methylene Blue. Cureus 2021. <a href="https://doi.org/10.7759/cureus.18596.">https://doi.org/10.7759/cureus.18596.</a></p><p>(53) Chang, Y.-L.; Chang, S.-T. The Effects of Intravascular Photobiomodulation on Sleep Disturbance Caused by Guillain-Barré Syndrome after Astrazeneca Vaccine Inoculation: Case Report and Literature Review. Medicine (Baltimore) 2022, 101 (6), e28758. <a href="https://doi.org/10.1097/MD.0000000000028758.">https://doi.org/10.1097/MD.0000000000028758.</a></p><p>(54) Chao, L. L. Improvements in Gulf War Illness Symptoms After Near-Infrared Transcranial and Intranasal Photobiomodulation: Two Case Reports. Mil. Med. 2019, 184 (9–10), e568–e574. <a href="https://doi.org/10.1093/milmed/usz037.">https://doi.org/10.1093/milmed/usz037.</a></p><p>(55) Bogdanova, Y.; Ho, V.; Martin, P.; Ho, M.; Yee, M.; Hamblin, M.; Naeser, M. Transcranial LED Treatment for Cognitive Dysfunction and Sleep in Chronic TBI: Randomized Controlled Pilot Trial. Arch. Phys. Med. Rehabil. 2017, 98 (10), e122–e123. <a href="https://doi.org/10.1016/j.apmr.2017.08.398.">https://doi.org/10.1016/j.apmr.2017.08.398.</a></p><p>(56) Chao, L. L. Effects of Home Photobiomodulation Treatments on Cognitive and Behavioral Function, Cerebral Perfusion, and Resting-State Functional Connectivity in Patients with Dementia: A Pilot Trial. Photobiomodulation Photomed. Laser Surg. 2019, 37 (3), 133–141. <a href="https://doi.org/10.1089/photob.2018.4555.">https://doi.org/10.1089/photob.2018.4555.</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=e0bfa66b8d91" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[First off … SMELL is still UP THERE as an IMPORTANT ingredient in this COVID mix… and its…]]></title>
            <link>https://drjoe-69223.medium.com/first-off-smell-is-still-up-there-as-an-important-ingredient-in-this-covid-mix-and-its-6f592bbd1223?source=rss-f1bafdba7014------2</link>
            <guid isPermaLink="false">https://medium.com/p/6f592bbd1223</guid>
            <dc:creator><![CDATA[Dr Joe DiDuro]]></dc:creator>
            <pubDate>Tue, 11 May 2021 14:44:47 GMT</pubDate>
            <atom:updated>2021-05-11T14:44:47.506Z</atom:updated>
            <content:encoded><![CDATA[<p>First off … SMELL is still UP THERE as an IMPORTANT ingredient in this COVID mix… and its connected to loss of cognitive function..</p><p>The number of correctly identified odors [ <strong>LOSS OF SMELL</strong> ] was significantly lower in COVID-19 than in controls and the Total MoCA score [ <strong>COGINITIVE ABILITY</strong> ] was significantly lower in COVID-19 patients than in controls (Pirker-Kees et al., 2021).</p><p>Cognitive performance indicated by MoCA was associated with number of correctly identified odors in COVID-19 patients and controls. OLFACTORY DYSFUNCTION is associated with <strong>cognitive impairment in controls and mild COVID-19</strong>. And again, LOSS OF SMELL may represent a potentially useful clinical biomarker <strong><em>for subtle and even subclinical neurological involvement in severe acute respiratory distress syndrome coronavirus-2 infection.</em></strong>(Pirker-Kees et al., 2021).</p><p>How about this number… In multivariate analyses, the odds for <strong>developing cognitive decline</strong> were <strong><em>18.1 times higher</em> among SARS‐CoV‐2 seropositive individuals </strong>(Del Brutto et al., 2021)</p><p>We already know that the <strong>loss of smell has been shown to be the first sign in a number of neurodegenerative conditions</strong>, including Alzheimer’s Disease and Parkinson’s Disease. (Churnin et al., 2019) (Dintica et al., 2019)<strong>.</strong></p><p><strong>NOW </strong>are beginning to understand that even <strong><em>Asymptomatic</em></strong> COVID-19 subjects secured lower scores in certain domains of the MoCA in comparison with the controls. (Amalakanti et al., 2021).</p><p>And guess what else… they even see this in <strong>YOUNGER ADULTS</strong>!</p><p>“Together, our results demonstrate that sustained sub-clinical cognitive impairments might be a common complication after recovery from COVID-19 in young adults, regardless of clinical course.” (Woo et al., 2020).</p><p><strong>The important take away is that our olfactory system is very sensitive to some factor that is also related to neurodegeneration and dementia,</strong> acting as a sort of canary-in-the-coal-mine for these diseases. PLUS the neurocognitive damage from COVID pretty much covers all ages — with or without symptoms!</p><p><strong>What’s the bottom line?</strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/596/0*ElBNvTE3bRjs4Pjj.jpg" /></figure><p>​</p><ul><li>Loss of your sense of smell is the seen EVEN in ASYMPTOMATIC PEOPLE that get COVID.</li><li>People EVEN YOUNG PEOPLE that get COVID end up with Cognitive Impairment and Decline [neurologic damage] — and not right away.</li><li><strong>Transcranial Photobiomodulation Therapy</strong> [tPBMT] has demonstrated to:</li><li>Restore your sense of smell</li><li>Assist in Neuroregeneration from neurologic conditions like MCI and Alzheimer’s</li><li>Improve recovery from COVID</li></ul><p>Recent research has shown <strong>Rapid Reversal of Cognitive Decline</strong> where the woman’s <strong>sense of smell was recovered</strong> as her cognitive scores improved <strong>from dementia to normal</strong>. To date this was the first time in the literature that one’s sense of smell can return in a neurodegenerative condition. The use of transcranial and intranasal photobiomodulation tPBMT was an integral part of the clients care plan. We know that this therapy increases blood flow to the area and may have an antiviral, anti-inflammatory and anti-aging effect also. (Salehpour et al., 2019) (Salehpour et al., 2020)</p><p><strong>How about a COVID treatment in the Safety of your OWN HOME?</strong></p><p>There has never been a better time to STAY HOME and GET BETTER. Effective Home Therapy is here. That is what the newest research is showing. (Sigman et al., 2020) (Fernandes et al., 2020) (Fekrazad &amp; Fekrazad, 2021)</p><p><strong>We are making it EASY with our 50% OFF SALE</strong></p><p>You are NOT SURE if you got COVID? But you want to to TAKE ACTION to protect your NERVOUS SYSTEM? There has never been a better time. We are offering 50% off our ProNeuroLIGHT intraNASAL Device to the first 20 people who order.</p><p><a href="https://app.kartra.com/communication/broadcast"><strong>http://www.proneurolight.com</strong></a></p><p><strong>LEARN MORE May 12th … Sign up for FREE for our</strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*08puOdNNRCfPMqeC.png" /></figure><p><strong>We are making it EASY with our 50% OFF SALE</strong></p><p>Check yourself. If you want to get better smell, [we can’t say smell better can we?], there has never been a better time. We are offering 50% off our ProNeuroLIGHT intraNASAL Device to the first 20 people who order.</p><p><a href="http://www.proneurolight.com/"><strong>http://www.proneurolight.com</strong></a></p><p><strong>REFERENCES</strong></p><p>Amalakanti, S., Arepalli, K. V. R., &amp; Jillella, J. P. (2021). Cognitive assessment in asymptomatic COVID-19 subjects. <em>Virusdisease</em>, 1–4. <a href="https://doi.org/10.1007/s13337-021-00663-w">https://doi.org/10.1007/s13337-021-00663-w</a></p><p>Churnin, I., Qazi, J., Fermin, C. R., Wilson, J. H., Payne, S. C., &amp; Mattos, J. L. (2019). Association Between Olfactory and Gustatory Dysfunction and Cognition in Older Adults. <em>American Journal of Rhinology &amp; Allergy</em>, <em>33</em>(2), 170–177. <a href="https://doi.org/10.1177/1945892418824451">https://doi.org/10.1177/1945892418824451</a></p><p>Del Brutto, O. H., Wu, S., Mera, R. M., Costa, A. F., Recalde, B. Y., &amp; Issa, N. P. (2021). Cognitive decline among individuals with history of mild symptomatic SARS-CoV-2 infection: A longitudinal prospective study nested to a population cohort. <em>European Journal of Neurology</em>. <a href="https://doi.org/10.1111/ene.14775">https://doi.org/10.1111/ene.14775</a></p><p>Dintica, C. S., Marseglia, A., Rizzuto, D., Wang, R., Seubert, J., Arfanakis, K., Bennett, D. A., &amp; Xu, W. (2019). Impaired olfaction is associated with cognitive decline and neurodegeneration in the brain. <em>Neurology</em>, <em>92</em>(7), e700–e709. <a href="https://doi.org/10.1212/WNL.0000000000006919">https://doi.org/10.1212/WNL.0000000000006919</a></p><p>Fekrazad, R., &amp; Fekrazad, S. (2021). The Potential Role of Photobiomodulation in Long COVID-19 Patients Rehabilitation. <em>Photobiomodulation, Photomedicine, and Laser Surgery</em>, <em>39</em>(4), 229–231. <a href="https://doi.org/10.1089/photob.2020.4984">https://doi.org/10.1089/photob.2020.4984</a></p><p>Fernandes, A. B., de Lima, C. J., Villaverde, A. G. J. B., Pereira, P. C., Carvalho, H. C., &amp; Zângaro, R. A. (2020). Photobiomodulation: Shining Light on COVID-19. <em>Photobiomodulation, Photomedicine, and Laser Surgery</em>, <em>38</em>(7), 395–397. <a href="https://doi.org/10.1089/photob.2020.4882">https://doi.org/10.1089/photob.2020.4882</a></p><p>Pirker-Kees, A., Platho-Elwischger, K., Hafner, S., Redlich, K., &amp; Baumgartner, C. (2021). Hyposmia Is Associated with Reduced Cognitive Function in COVID-19: First Preliminary Results. <em>Dementia and Geriatric Cognitive Disorders</em>, 1–6. <a href="https://doi.org/10.1159/000515575">https://doi.org/10.1159/000515575</a></p><p>Salehpour, F., Gholipour-Khalili, S., Farajdokht, F., Kamari, F., Walski, T., Hamblin, M. R., DiDuro, J. O., &amp; Cassano, P. (2020). Therapeutic potential of intranasal photobiomodulation therapy for neurological and neuropsychiatric disorders: A narrative review. <em>Reviews in the Neurosciences</em>, <em>31</em>(3), 269–286. <a href="https://doi.org/10.1515/revneuro-2019-0063">https://doi.org/10.1515/revneuro-2019-0063</a></p><p>Salehpour, F., Hamblin, M. R., &amp; DiDuro, J. O. (2019). Rapid Reversal of Cognitive Decline, Olfactory Dysfunction, and Quality of Life Using Multi-Modality Photobiomodulation Therapy: Case Report. <em>Photobiomodulation, Photomedicine, and Laser Surgery</em>, <em>37</em>(3), 159–167. <a href="https://doi.org/10.1089/photob.2018.4569">https://doi.org/10.1089/photob.2018.4569</a></p><p>Sigman, S., Mokmeli, S., &amp; Vetrici, M. (2020). Adjunct low level laser therapy (LLLT) in a morbidly obese patient with severe COVID-19 pneumonia: A case report. <em>Canadian Journal of Respiratory Therapy</em>, <em>56</em>, 52–56. <a href="https://doi.org/10.29390/cjrt-2020-022">https://doi.org/10.29390/cjrt-2020-022</a></p><p>Woo, M. S., Malsy, J., Pöttgen, J., Seddiq Zai, S., Ufer, F., Hadjilaou, A., Schmiedel, S., Addo, M. M., Gerloff, C., Heesen, C., Schulze Zur Wiesch, J., &amp; Friese, M. A. (2020). Frequent neurocognitive deficits after recovery from mild COVID-19. <em>Brain Communications</em>, <em>2</em>(2), fcaa205. <a href="https://doi.org/10.1093/braincomms/fcaa205">https://doi.org/10.1093/braincomms/fcaa205</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=6f592bbd1223" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Loss of smell in mild Covid-19 cases occurs 86% of the time, study says]]></title>
            <link>https://drjoe-69223.medium.com/loss-of-smell-in-mild-covid-19-cases-occurs-86-of-the-time-study-says-5068e0de65a0?source=rss-f1bafdba7014------2</link>
            <guid isPermaLink="false">https://medium.com/p/5068e0de65a0</guid>
            <category><![CDATA[photobiomodulation]]></category>
            <category><![CDATA[red-light-therapy]]></category>
            <category><![CDATA[covid19]]></category>
            <category><![CDATA[anosmia]]></category>
            <category><![CDATA[loss-of-smell]]></category>
            <dc:creator><![CDATA[Dr Joe DiDuro]]></dc:creator>
            <pubDate>Tue, 11 May 2021 14:04:41 GMT</pubDate>
            <atom:updated>2021-05-11T14:04:41.682Z</atom:updated>
            <content:encoded><![CDATA[<p>Some 86% of people with <strong>mild cases</strong> of Covid-19 lose their sense of smell and taste but recover it within six months, according to a<a href="https://onlinelibrary.wiley.com/doi/full/10.1111/joim.13209"> new study</a> of over 2,500 patients from 18 European hospitals.(Lechien et al. n.d.)</p><p>[ A case of Covid-19 was considered mild if there was no evidence of viral pneumonia or loss of oxygen and the patient was able to recover at home]</p><p>This could be anyone…</p><p>And worse.. The sense of smell reappeared after an average of 18 to 21 days, the study found, but about 5% of people had not recovered olfactory function at six months.</p><p>Anosmia, which is a loss of smell, and therefore taste, <a href="https://www.cnn.com/2020/07/10/health/covid-19-symptoms-new-knowledge-wellness/index.html">has been suggested as an early sign of Covid-19</a>. It can occur without any prior warning, not even a stuffy nose.(Gautier and Ravussin 2020)</p><p>“Anosmia, in particular, has been seen in patients ultimately testing positive for the coronavirus with no other symptoms,” according to the<a href="https://www.entnet.org/content/aao-hns-anosmia-hyposmia-and-dysgeusia-symptoms-coronavirus-disease"> American Academy of Otolaryngology-Head and Neck Surgery</a>.(139939 2020)</p><h3>Moderate to Severe Covid-19</h3><p>Comparatively, the study found that only 4% to 7% of people with moderate to severe symptoms of Covid-19 lost their ability to smell and taste. (Lechien et al. n.d.)</p><p>People with moderate Covid‐19 had “clinical signs of pneumonia,” the study said, such as cough, fever and difficulty breathing. Those with critical cases of the disease suffered severe respiratory distress, and were more likely to be older and have “hypertension, diabetes, gastric disorders, renal, respiratory, heart, liver and neurological disorders.”</p><p>The study, which published Monday in the Journal of Internal Medicine, found a higher rate of olfactory dysfunction in younger patients compared to the elderly, but that association needs further analysis, the researchers said. (Lechien et al. n.d.)</p><p>Smell loss is common BUT What about RECOVERY?</p><p>Of course, not everyone who flunks a smell test is going to have coronavirus. Any respiratory virus, such as cold or flu, will temporarily impact smell and taste, sometimes even permanently.</p><p>That means that they harm the olfactory nerve and it becomes essentially nonfunctional,” he added. “Many of those cases can recover smell with time, but sometimes it’s a permanent loss.”</p><p>A partial or complete chronic loss of smell is incredibly common, Munger said, affecting millions of Americans long before the novel coronavirus burst upon the scene.</p><p>“About 13% of the population has a significant smell or taste impairment,” he said.</p><p>Besides cold and flu, other causes of smell loss include nasal polyps, tumors, neurodegenerative diseases like Alzheimer’s or Parkinson’s, and traumatic brain injury or head trauma, including whiplash.</p><p>“If someone has been in an auto accident or had a whiplash injury or head injury, that could also impact the little nerves as they go from the brain down to the nose,” Voigt said. “So a whiplash injury could also cause a permanent loss of sense of smell.”</p><p>A loss of taste is commonly associated with the loss of smell, because we rely on smell to identify flavors. But there can also be medical reasons: Some medications can affect taste; chemotherapy and radiation therapy can certainly disrupt taste; and then there is physical damage, such as nerves severed during dental surgeries.</p><p>My gosh . . .</p><p>Different underlying mechanisms have been advocated to explain the presence of anosmia in patients with COVID-19. These include olfactory cleft syndrome, direct damage of olfactory sensory neurons, postviral anosmia syndrome, cytokine storm, and/or impairment of the olfactory perception centers in the brain. (Saussez, Lechien, and Hopkins 2020)</p><p>Anosmia is associated with depression, loss of appetite, and diminished quality of life, but it’s also an invisible and underappreciated phenomenon.(Elkholi, Abdelwahab, and Abdelhafeez 2021)</p><p>parosmia</p><p>n. A distortion of the sense of smell, as in smelling odors that are not present.</p><p>n. In pathology, a perversion of the sense of smell; olfactory illusion.</p><p>n. A distorted sense of smell, often resulting in phantom, non-existent, and mostly unpleasant, smells.</p><p>Complete recovery of smell function after a mean follow up of 229 days was found in 52% of patients, while 48% reported only partial recovery. (Biadsee et al. 2020)</p><p>Olfactory and/or gustatory dysfunction have been widely reported as one of the sole initial manifestations of COVID-19 infection.(Kaye et al. 2020) (Paderno et al. 2020)</p><p>Several therapies such as zinc, intranasal corticoid injections and systemic steroids have been used in post-viral OD, but have never proven to be effective [22]. (Hura et al. 2020)</p><p>To date, the only approved treatment is daily and long-term olfactory rehabilitation, which could improve the olfactory capacities of patients up to 30% [23]. (Hummel et al. 2009)</p><p>However, whether olfactory rehabilitation could be effective in COVID-19 patients with anosmia still remains to be demonstrated.(Cousyn et al. 2021)</p><p>As such, based on our current understanding of the available evidence, there may be additional risk associated with systemic steroid therapy for the treatment of COVID-19.(Hura et al. 2020)</p><p>Recent research has shown that <strong>Transcranial Photobiomodulation Therapy</strong> [tPBMT] was able to restore the sense of smell as her cognitive scores improved from dementia to normal. (Salehpour, Hamblin, and DiDuro 2019). To date this was the first time in the literature that one’s sense of smell was restored in a neurodegenerative condition. The use of transcranial and intranasal photobiomodulation tPBMT was an integral part of the clients care plan. We know that this therapy increases blood flow to the nasal area and olfactory nerves and may have an antiviral, anti-inflammatory and anti-aging effect also. (Salehpour et al. 2020)</p><p>139939. 2020. “AAO-HNS: Anosmia, Hyposmia, and Dysgeusia Symptoms of Coronavirus Disease.” <em>American Academy of Otolaryngology-Head and Neck Surgery</em>. Retrieved May 8, 2021 (<a href="https://www.entnet.org/content/aao-hns-anosmia-hyposmia-and-dysgeusia-symptoms-coronavirus-disease">https://www.entnet.org/content/aao-hns-anosmia-hyposmia-and-dysgeusia-symptoms-coronavirus-disease</a>).</p><p>Biadsee, Ameen, Ameer Biadsee, Firas Kassem, Or Dagan, Shchada Masarwa, and Zeev Ormianer. 2020. “Olfactory and Oral Manifestations of COVID-19: Sex-Related Symptoms — A Potential Pathway to Early Diagnosis.” <em>Otolaryngology–Head and Neck Surgery</em> 163(4):722–28. doi: 10.1177/0194599820934380.</p><p>CNN, Sandee LaMotte. n.d. “Loss of Smell in Mild Covid-19 Cases Occurs 86% of the Time, Study Says.” <em>CNN</em>. Retrieved May 4, 2021 (<a href="https://www.cnn.com/2021/01/06/health/loss-of-smell-covid-study-wellness/index.html">https://www.cnn.com/2021/01/06/health/loss-of-smell-covid-study-wellness/index.html</a>).</p><p>Cousyn, L., B. Sellem, R. Palich, D. Bendetowicz, R. Agher, C. Delorme, R. Tubiana, M. A. Valantin, S. Seang, L. Schneider, A. Fayçal, Y. Dudoit, B. Abdi, A. Ndoadoumgue, L. Assoumou, C. Katlama, and COVIDOM-19 PSL group. 2021. “Olfactory and Gustatory Dysfunctions in COVID-19 Outpatients: A Prospective Cohort Study.” <em>Infectious Diseases Now</em>. <a href="https://pubmed.ncbi.nlm.nih.gov/33766735/">doi: 10.1016/j.idnow.2021.03.004.</a></p><p>Elkholi, Safaa Mostafa Ali, Mohamed Kamal Abdelwahab, and Marwa Abdelhafeez. 2021. “Impact of the Smell Loss on the Quality of Life and Adopted Coping Strategies in COVID-19 Patients.” <em>European Archives of Oto-Rhino-Laryngology</em>. <a href="https://pubmed.ncbi.nlm.nih.gov/33464401/">doi: 10.1007/s00405–020–06575–7</a>.</p><p>Gautier, Jean-François, and Yann Ravussin. 2020. “A New Symptom of COVID-19: Loss of Taste and Smell.” <em>Obesity (Silver Spring, Md.)</em> 28(5):848. <a href="https://pubmed.ncbi.nlm.nih.gov/32237199/">doi: 10.1002/oby.22809.</a></p><p>Hummel, Thomas, Karo Rissom, Jens Reden, Aantje Hähner, Mark Weidenbecher, and Karl-Bernd Hüttenbrink. 2009. “Effects of Olfactory Training in Patients with Olfactory Loss.” <em>The Laryngoscope</em> 119(3):496–99. doi: <a href="https://onlinelibrary.wiley.com/doi/abs/10.1002/lary.20101">https://doi.org/10.1002/lary.20101.</a></p><p>Hura, Nanki, Deborah X. Xie, Garret W. Choby, Rodney J. Schlosser, Cinthia P. Orlov, Stella M. Seal, and Nicholas R. Rowan. 2020. “Treatment of Post-Viral Olfactory Dysfunction: An Evidence-Based Review with Recommendations.” <em>International Forum of Allergy &amp; Rhinology</em> 10(9):1065–86. doi: <a href="https://pubmed.ncbi.nlm.nih.gov/32567798/">https://doi.org/10.1002/alr.22624.</a></p><p>Kaye, Rachel, C. W. David Chang, Ken Kazahaya, Jean Brereton, and James C. Denneny. 2020. “COVID-19 Anosmia Reporting Tool: Initial Findings.” <em>Otolaryngology–Head and Neck Surgery</em> 163(1):132–34. <a href="https://pubmed.ncbi.nlm.nih.gov/32340555/">doi: 10.1177/0194599820922992.</a></p><p>Lechien, J. R., C. M. Chiesa‐Estomba, E. Beckers, V. Mustin, M. Ducarme, F. Journe, A. Marchant, L. Jouffe, M. R. Barillari, G. Cammaroto, M. P. Circiu, S. Hans, and S. Saussez. n.d. “Prevalence and 6-Month Recovery of Olfactory Dysfunction: A Multicentre Study of 1363 COVID-19 Patients.” <em>Journal of Internal Medicine</em> n/a(n/a). <a href="https://onlinelibrary.wiley.com/doi/full/10.1111/joim.13209">doi: https://doi.org/10.1111/joim.13209</a>.</p><p>Paderno, Alberto, Davide Mattavelli, Vittorio Rampinelli, Alberto Grammatica, Elena Raffetti, Michele Tomasoni, Tommaso Gualtieri, Stefano Taboni, Silvia Zorzi, Francesca Del Bon, Davide Lombardi, Alberto Deganello, Luca Oscar Redaelli De Zinis, and Alberto Schreiber. 2020. “Olfactory and Gustatory Outcomes in COVID-19: A Prospective Evaluation in Nonhospitalized Subjects.” <em>Otolaryngology–Head and Neck Surgery</em> 163(6):1144–49. <a href="https://journals.sagepub.com/doi/10.1177/0194599820939538">doi: 10.1177/0194599820939538.</a></p><p>Salehpour, Farzad, Sevda Gholipour-Khalili, Fereshteh Farajdokht, Farzin Kamari, Tomasz Walski, Michael R. Hamblin, Joseph O. DiDuro, and Paolo Cassano. 2020. “Therapeutic Potential of Intranasal Photobiomodulation Therapy for Neurological and Neuropsychiatric Disorders: A Narrative Review.” <em>Reviews in the Neurosciences</em> 31(3):269–86. doi: 10.1515/revneuro-2019–0063.</p><p>Salehpour, Farzad, Michael R. Hamblin, and Joseph O. DiDuro. 2019. “Rapid Reversal of Cognitive Decline, Olfactory Dysfunction, and Quality of Life Using Multi-Modality Photobiomodulation Therapy: Case Report.” <em>Photobiomodulation, Photomedicine, and Laser Surgery</em> 37(3):159–67. doi: 10.1089/photob.2018.4569.</p><p>Saussez, Sven, Jerome R. Lechien, and Claire Hopkins. 2020. “Anosmia: An Evolution of Our Understanding of Its Importance in COVID-19 and What Questions Remain to Be Answered.” <em>European Archives of Oto-Rhino-Laryngology</em>. doi: 10.1007/s00405–020–06285–0.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=5068e0de65a0" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>